Category: Mergers & AcquisitionsSyndicate content

ConvaTec said to explore 2015 sale

August 19, 2014 by Brad Perriello

ConvaTec is reportedly weighing a sale of the private-equity-owned medical device company next year, even as interest in a Medtronic-like inversion deal mounts from C.R. Bard, CareFusion and 3M.

ConvaTec said to explore 2015 sale

Medtronic and Covidien reveal their integration teams

August 19, 2014 by Arezu Sarvestani

Medtech titans Medtronic and Covidien name more than 45 people to coordinate the finer points of their merger.

Medtronic and Covidien reveal their integration dream-team

LeMaitre pays $7.7M for Xenotis and its bio-graft

August 18, 2014 by Arezu Sarvestani

LeMaitre Vascular acquires another "under-marketed" device in Xenotis and its Omniflow II biological graft.

LeMaitre pays $7.7M for Xenotix and its bio-grafts

LeMaitre Vascular (NSDQ:LMAT) got a Wall Street boost today after reporting that it acquired graft-maker Xenotis is a deal valued at $7.7 million.

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

August 18, 2014 by Brad Perriello

Allergan CFO Jeff Edwards is stepping down amid a $44 billion hostile takeover bid from Valeant Pharmaceuticals and Pershing Square Capital Management.

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

Allergan (NYSE:AGN) said today that longtime CFO Jeff Edwards is stepping down to honor a commitment he made to his family earlier this year, replaced by treasurer Jim Hindman effective immediately.

Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal

August 15, 2014 by Brad Perriello

Medtronic CEO Omar Ishrak seeks to reassure employees amid the political fallout over the tax inversion aspects of its $43 billion deal to acquire Covidien.

Ishrak seeks to reassure employees on Medtronic-Covidien deal

Will Medtronic follow Walgreen and abandon inversion in Covidien deal?

August 15, 2014 by Brad Perriello

Bearish options trades on Covidien are driven by speculation that Medtronic will follow Walgreen in abandoning plans for a so-called tax inversion deal, Bloomberg reports.

Will Medtronic follow Walgreen and abandon inversion in Covidien deal?

Medtronic founder Bakken backs Covidien buy

August 15, 2014 by Brad Perriello

Earl Bakken, the founder of Medtronic, tells employees he's behind the company's $43 billion acquisition of Covidien and its potential to save a life every second.

Medtronic founder Bakken backs Covidien buy
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp